Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Open Access
- 1 December 2011
- journal article
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 3, 79-91
Abstract
Peer reviewed article authored by (Lewiecki EM). Read article or submit your manuscript for publishing.Keywords
This publication has 69 references indexed in Scilit:
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialOsteoporosis International, 2012
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Osteoporosis International, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast CancerJournal of Clinical Oncology, 2008
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivoBlood, 2007
- Hip fractures in the elderly: A world-wide projectionOsteoporosis International, 1992